Island Pharmaceuticals Announces 2nd Phase in Dengue Fever Trial
After the progress update on July 3, 2024, Island submitted the final report of its Single Ascending Dose Phase 1 clinical study to the US Food and Drug Administration (FDA). On the same day, Island also submitted the proposed protocol for the upcoming ISLA-101 Phase 2 clinical study. On 8 May 2024, Island announced SUNY Upstate New York has allocated a Congressionally Directed Medical Research Program grant to support the coming ISLA-101 clinical study directly. Because of this grant to cover trial costs, the remaining cost to Island for the full study is around US $1.08m, which is substantially lower than previous estimates.
Island Pharmaceuticals Announces 2nd Phase in Dengue Fever Trial